Articles By Jack Cush, MD
#ACR 2024 BEST Abstracts from Day 2
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.
Read Article
ACR 2024 - Day 2 Report
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Read Article
ACR 2024 - Day 1 Report
ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings. The meeting began with a flip: the plenary sessions started at 9AM and the poster session began at 1030 AM. Below are some of the highlights from day one in Washington, DC.
Read Article
#ACR 2024 BEST Abstracts from Day 1
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC. Here are some of the best abstracts from Saturday Nov. 16th.
Read Article
ACR 2024 - Featured Industry Presentations
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read Article
ACR24 Preview Podcast (11.15.2024)
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
Read Article
A Polygenic Model for Still's Disease
Adult-onset Still's disease (AOSD) is systemic autoinflammatory disorder of unknown etiology. It is considered among the febrile autoinflammatory etiologies.
Read Article
No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse cardiovascular events (MACE) in JAKi vs TNFi use in IBD.
Read Article
Weight Loss from Anti-Obesity Medications Prevents Gout
A population based study looked at the effect of the weight loss drug, Orlistat, in obese individuals. Compared to those untreated, orlistat over 1 year was associated with significant weight loss and significantly lower risks of incident gout and recurrent gout flares among overweight or obese people.
Read Article
Early RA Journey - Patient Perspectives and Uncertainties
Canadian early RA (ERA) patients were interviewd to depict their perspectives from onset and diagnosis to referral and care. This report highlights the importance of patient pain and primary care physician (PCP) intake and referral. PCP and HCP delays in referral to a specialist still exist.
Read Article